Doctor Claims Gene Hackman's Wife Called Him 24 Hours After Police Say She Died
A doctor has revealed Gene Hackman's wife, Betsy Arakawa, didn't die on February 11, as officers claim, because she called his clinic on February 12.
Hackman, Arakawa, and one of their three dogs were found dead in their home in New Mexico on February 26, with the initial suspicion being that they died due to carbon monoxide poisoning.
However, law enforcement officials from Santa Fe County revealed that Arakawa died of Hantavirus on February 11, while Hackman died seven days later due to hypertensive atherosclerotic cardiovascular disease, with Alzheimer's being a contributing factor.
The circumstances surrounding Arakawa and Hackman's deaths continue to generate confusion, with a doctor now adding another angle to the mystery.
On Saturday, Dr. Josiah Child told the Daily Mail that officers were wrong about Arakawa's day of death.
He said, "Mrs. Hackman didn't die on February 11 because she called my clinic on February 12."
Child, a former emergency care specialist who now runs Cloudberry Health in Santa Fe, explained further, "She'd called me a couple of weeks before her death to ask about getting an echocardiogram [heart scan] for her husband. She was not a patient of mine, but one of my patients recommended Cloudberry to her."
He also said, "She made an appointment for herself for February 12. It was for something unrelated to anything respiratory."
The doctor said Arakawa canceled her appointment two days before she was to see him because Gene Hackman was unwell.
He also revealed, "She called back on the morning of February 12 and spoke to one of our doctors who told her to come in that afternoon."
Dr. Child said, "We made her an appointment but she never showed up. She did not show any symptoms of respiratory distress."
He added, "The appointment wasn't for anything related to hantavirus. We tried calling her a couple of times with no reply."
The doctor's revelations that Arakawa was alive on the day the coroner claimed she died adds another layer of mystery to an already stressful situation.
However, Dr. Child is also disputing that hantavirus is the cause of Arakawa's death as she showed no signs of "respiratory distress."
He said, "I am not a hantavirus expert but most patients who have that diagnosis die in hospital. It is surprising that Mrs. Hackman spoke to my office on the phone on February 10 and again on February 12 and didn't appear in respiratory distress."
Meanwhile, a Los Angeles-based doctor spoke to the outlet on Sunday and cast more doubt on hantavirus being the cause of Arakawa's demise.
They said, "Medical professionals are all scratching their heads over hantavirus as the cause of death. Respiratory failure is not sudden – it is something that worsens over several days."
The doctor concluded, "Most people get admitted to the ER [emergency room] because they are having trouble breathing. It's exceedingly rare for a seemingly healthy 65-year-old to drop dead of it. In fact, no one's heard of such a thing."
On February 11, 2025, Arakawa, 65, reportedly carried out her usual activities, visiting a grocery store, pharmacy, and pet food shop before returning home to Santa Fe.
Authorities believe she died that same day from hantavirus, a rare but deadly disease linked to rodent droppings.
Following her passing, there was no further communication or activity from her.
Hackman, 95, who suffered from Alzheimer's disease, was likely unaware of his wife's death. His pacemaker data recorded heart activity on February 17, with an irregular rhythm on February 18, suggesting he passed away that day due to heart disease.
Arakawa and Hackman's bodies were found on February 26 when a maintenance worker reported them unresponsive. Authorities ruled both deaths as natural causes—Arakawa from hantavirus and Hackman from heart disease, with Alzheimer's as a contributing factor.
Meanwhile, Bruce Willis' wife, Emma Heming Willis, reflected on the couple's death, stressing the need to support caregivers.
She highlighted how Arakawa, Hackman's caregiver, passed away a week before him, reinforcing the challenges caregivers face.
Drawing from her own experience caring for Bruce, who has frontotemporal dementia, Emma urged people to recognize caregivers' struggles.
She debunked the myth that caregivers "have it all figured out," insisting they also need care. In an Instagram post, she emphasized, "Caregivers need care too. Period. Full stop."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Upturn
an hour ago
- Business Upturn
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
Darmstadt, Germany: Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the primary endpoint of BICLA dose-response relationship at Week 24 was not met Data show encouraging efficacy in a large subgroup of SLE patients with active cutaneous manifestations at baseline, including improved response rates in key disease activity measurements There is a substantial unmet treatment need for the estimated 70-80% of SLE patients who experience active cutaneous manifestations, which can profoundly impact quality of life1 Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an investigational, oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE). Although it did not meet the primary endpoint of dose-response relationship, when compared to placebo, enpatoran demonstrated improvements in measures of both systemic and cutaneous disease activity in prespecified SLE subpopulations despite standard of care (SoC), including those with active cutaneous manifestations at baseline [(CLASI-A) ≥8], and was overall well tolerated. These findings will be presented in a late-breaking oral presentation at the 2025 European Congress of Rheumatology (EULAR) in Barcelona (Abstract # LB0004). 'Analyses of Cohort B contribute to our understanding of enpatoran's potential to address the critical unmet needs for patients living with lupus, including those experiencing significant skin manifestations. These manifestations are often part of the systemic activity or flare, which can be painful and have a considerable impact on quality of life,' said principal investigator Prof. Eric Morand, from Monash University and Monash Health. 'The improvements observed in key disease measures represent a meaningful advancement in our ongoing investigation of the TLR7/8 inhibition approach for patients insufficiently managed by current therapies.' WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of oral enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus SoC over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and cutaneous lupus erythematosus (CLE). Cohort B of the study was designed to evaluate the dose-response relationship of enpatoran in reducing disease activity, based on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at Week 24 and enrolled SLE patients who had moderate or severe active disease despite SoC. Cohort B showed positive results in secondary and exploratory endpoints and within prespecified patient subpopulations. In patients with active skin disease (CLASI-A ≥8), BICLA response rates were up to 58.6% while placebo response rates were 31.7%, and up to 60.5% of patients receiving enpatoran showed a CLASI-70 response, compared with 26.8% for placebo, at Week 24. In addition, the subgroups of patients with high corticosteroid (prednisone-equivalent ≥10 mg/day) use and those with high interferon gene signature (IFN-GS) at baseline also showed higher and relevant BICLA response rates for enpatoran compared to placebo. As presented earlier this year at LUPUS 2025, Cohort A analyses from the WILLOW study showed clinically meaningful improvement in disease activity in patients with CLE and mild SLE with active lupus rash at Weeks 16 and 24. Overall, for skin-related signs and symptoms, comparable improvements were observed in Cohort B relative to Cohort A, reinforcing the potential efficacy of enpatoran in patients with cutaneous manifestations of lupus erythematosus with or without systemic disease. 'The efficacy and tolerability results from Cohort B, including among those with active skin involvement—a manifestation that affects most lupus patients—are consistent with our observations from Cohort A. The lupus rash is not only a visible symptom but is also closely linked to the underlying systemic activity of lupus,' said Jan Klatt, Head of Development Unit Neurology & Immunology for the Healthcare business of Merck. 'We are set to initiate regulatory discussions with key health authorities to determine the most effective pathway for bringing enpatoran to patients.' Enpatoran was well-tolerated and exhibited a manageable safety profile consistent with previous studies, with no new safety signals identified. Rates of treatment-emergent adverse events (TEAEs) were comparable between all enpatoran arms and placebo, ranging from 60.6% to 64.2%, and the most frequently reported TEAEs were infections and infestations. These results further support the anticipated favorable safety profile of enpatoran. About Enpatoran Enpatoran is a selective Toll-like receptor (TLR)7/8 inhibitor under investigation for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). By inhibiting TLR7/8 activation, enpatoran may help reduce pro-inflammatory cytokines and autoantibody production, potentially addressing underlying mechanisms of chronic inflammation and disease progression in lupus. With its novel proposed mechanism of action and oral administration, enpatoran has the potential to be a first-in-class treatment for patients across lupus conditions. Enpatoran is currently under clinical investigation and is not approved for any use anywhere in the world. About the Phase 2 WILLOW Clinical Study WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). The study incorporates a basket design, including two cohorts – Cohort A including patients with CLE or SLE with active lupus rash and Cohort B including patients with active SLE. The WILLOW study aims to advance the understanding of enpatoran's therapeutic potential and to help address significant unmet needs in lupus treatment. About Lupus Erythematosus Lupus erythematosus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, and other organs. It occurs when the immune system mistakenly attacks healthy tissues, leading to inflammation, pain, and potential organ damage. There are multiple types of lupus, with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) being two primary forms. Symptoms can range from mild to life-threatening, often including fatigue, joint pain, rashes, and organ involvement. Lupus disproportionately impacts women and people of color, and despite available treatments, many patients experience unmet needs due to limited efficacy or side effects. Merck in Neurology and Immunology Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company's current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck's commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and generalized myasthenia gravis (gMG). About Merck Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries. The company holds the global rights to the name and trademark 'Merck' internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service. 1 Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. PMID: 22879850; PMCID: PMC3391953. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
2 hours ago
- Yahoo
New Hantavirus Warning Issued Months After Gene Hackman's Wife's Death
New Hantavirus Warning Issued Months After Gene Hackman's Wife's Death originally appeared on Parade. Gene Hackman's wife, Betsy Arakawa, tragically passed away after contacting Hantavirus — a rare but serious disease carried by rodents. Now, the Nevada Department of Health and Human Services and the Nevada Department of Wildlife are urging residents to take extra precautions. The agency confirmed two additional cases of the virus in the state on Tuesday, June 10. 'We urge people to be aware of any signs of rodent activity and to take precautions to reduce the risk of exposure to hantavirus.' Melissa Bullock, the state's medical epidemiologist, emphasized the importance of early detection. 🎬SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox🎬 'Anyone who has been in contact with rodents, nests or droppings and subsequently develops symptoms consistent with hantavirus pulmonary syndrome should see a health care provider immediately,' she stated in a press release. Hantavirus is an infectious disease that's typically spread through exposure to infected rodents. Transmission can occur through contact with the animal's urine, droppings or saliva. The early symptoms of HPS include fever, fatigue and muscle aches, followed by coughing and shortness of breath. According to the Centers for Disease Control and Prevention, HPS is a severe and potentially fatal illness — nearly 4 in 10 people who are infected pass away. However, it can be treated if caught early through blood tests and proper medical care. 'As warmer weather arrives, people will be more active in areas such as sheds, barns, trailers, garages and cabins where deer mice have nested or left droppings,' the agency noted. To reduce the risk of hantavirus exposure, health agencies recommend the following, including: Secure garbage in containers with tight-fitting lids. Seal gaps, cracks, or holes in structures to keep mice out. Keep areas clean and free of clutter or food sources. Use gloves and a well-fitted N95 mask when cleaning areas with signs of rodent activity. In March, officials revealed that Arakawa died from hantavirus pulmonary syndrome. The New Mexico Health Department later revealed that investigators had found signs of "rodent entry" in structures on the couple's property. New Hantavirus Warning Issued Months After Gene Hackman's Wife's Death first appeared on Parade on Jun 13, 2025 This story was originally reported by Parade on Jun 13, 2025, where it first appeared.
Yahoo
6 hours ago
- Yahoo
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
TAINAN, June 12, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (β-amyloid clearance), and anti-inflammatory effects (through NF-κB inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment. The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia. Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO. With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease. About Merry Life Biomedical Company Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs. Media ContactDr. Ih-Jen SuMerry Life Biomedical Company, +886-910-902-296Email: suihjen0704@ View original content to download multimedia: SOURCE Merry Life Biomedical Company, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data